January 14, 2011 Press Release Briefingwire.com -- Immune Response BioPharma Announces Plans to Develop NeuroVax & Pursue Clinical Development of the Novel MS Vaccine, Partnering & Capital Raising Plans to Fund Development and Seek Orphan FDA Designation of NeuroVax an Accelerated Pathway to Eventual FDA Approval.
Immune Response BioPharma, Fredericksburg, Virginia Today 1/14/2010 privately held announces Formation and Intentions to develop the Multiple Sclerosis Novel Vaccine NeuroVax a once a month dosing therapeutic vaccine. Additionally the company plans to partner with experienced and financially stable partners for manufacturing and clinical development. Furthermore the company intends to work closely with the FDA to secure an IND, and seek Orphan Designation for this valuable treatment option for MS patients. Also the company intends to raise an adequate amount of capital to fund development and operations.
NeuroVax represents hope to patients suffering from this awful disease multiple sclerosis as well it offers unique benefits such as once a month dosing, safe and effective and a unique mechanism of action with TCR action triggering immune responses. This treatment option will give doctors and patients a valuable and beneficial way to treat this debilitating disease. NeuroVax maybe become drug/vaccine treatment of choice for those suffering from MS. This is a viable treatment alterative and has a safe and effective profile which should be of enormous benefit to those afflicted by this terrible disease. This is potentially a Billion dollar drug/vaccine thus with such a valuable treatment option choosing the right partner is develop NeuroVax is important.
The company is in the process of entering a dialogue with qualified and experienced manufacturer and financially stable partners who can work closely with the FDA and eventually get the vaccine through the clinical trial process in a timely and efficient manner. Orphan designation for NeuroVax would provide a 7 year exclusivity and would be eligible for a 50% tax credit for development.
“Today is a great day for MS patients and this exciting therapeutic novel treatment for MS will hopefully benefit the estimated 2 million plus patients suffering from this debilitating disease. Funding for the trials should not be an issue as this is an important drug/vaccine that perhaps is the best treatment option for MS and it may become treatment of choice for MS. I believe the Funding will come and the company will select the right partners to make this treatment a reality for those suffering from MS, as well the manufacturing process and partners look promising” Chief Operating Officer, Mr. Buswell.
Immune Response BioPharma is a diversified biopharmaceutical company engaged in the process of developing lifesaving drugs and therapeutic vaccines in the auto-immune, infectious disease areas. The company has a deep pipeline of experimental drugs it plans to develop. Plans to raise capital is neither an offer nor solicitation for sale of securities. Safe Harbor disclosure. Immune Response BioPharma may be found on the world wide web at www.immuneresponsebiopharma.com
Media Contact Info Info@immuneresponsebiopharma.com
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va
